OS Therapies Shares Positive 1-year Survival And Safety Data For Ost-her2 At Osteosarcoma Conference
June 30, 2025
Company also provides regulatory update on comparator for OST-HER2 Phase 2b Trial in the Prevention or Delay of Recurrence in Fully Resected, Lung Metastatic Osteosarcoma